GSK@100: Reinvention, resilience critical to journey, says MD
GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.
pharmaphorum2d
‘Real world’ COPD trial gives GSK a dose of reality
Topline results from the groundbreaking Salford Lung Study are encouraging for GSK's new respiratory drug - but the 'real world' story isn't quite so simple. GlaxoSmithKline (GSK) has announced ...
Reuters on MSN28d
GSK sues Moderna for US patent infringement over COVID, RSV vaccines
(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of ...
GlobalData on MSN6d
GSK’s RSV vaccine approved in Canada for adults aged 50 to 59
GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.
Nasdaq11d
GlaxoSmithKline Updates Share Capital and Voting Rights
GlaxoSmithKline (GSK) has released an update. GlaxoSmithKline (GSK) has announced that its issued share capital as of October 31, 2024, consists of over 4.3 billion ordinary shares, with a ...
Business Insider5d
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...
pharmaphorum2d
What makes GSK the number one pharmaceutical company in Egypt?
GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...
GSK Pharma stock gains over 3% after profit, revenue boost in Q2 earnings
Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...
GlobalData on MSN13d
GSK to acquire Chimagen’s CMG1A46 for autoimmune disease
GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell-driven autoimmune diseases, for $300m upfront.
DPA International on MSN13d
British pharmaceutical company GSK reports drop in Q3 pre-tax profit
British pharmaceutical company GSK reported on Wednesday that its third-quarter profit before tax dropped to £64 million ($83 ...